Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Cited by (1,010)

Items 201–300 of 1,010

1. Immune Checkpoint Inhibitor Therapy in Oncology
   Sean Tan, Daphne Day, Stephen James Nicholls, Eva Segelov · 2022 · JACC CardioOncology
2. Hypopharyngeal cancer: A state of the art review
   Jonathan C. Garneau, Richard Lorne Bakst, Brett A. Miles · 2018 · Oral Oncology
3. Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments
   Jong W. Yu, Sabyasachi Bhattacharya, Niranjan Yanamandra, David Kilian, Hong Shi, Sapna Yadavilli, Yuliya V. Katlinskaya, Heather Kaczynski, Michael Conner, William Benson et al. · 2018 · PLoS ONE
4. Tumor Immunity and Immunotherapy for HPV-Related Cancers
   Achraf A. Shamseddine, Bharat Burman, Nancy Y. Lee, Dmitriy Zamarin, Nadeem Riaz · 2021 · Cancer Discovery
5. Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
   Aleksandar Obradovic, Diana K. Graves, Michael J. Korrer, Yu Wang, Sohini Roy, Abdullah Naveed, Yaomin Xu, Adam Luginbuhl, Joseph Curry, Michael K. Gibson et al. · 2022 · Clinical Cancer Research
6. Treatment after progression in the era of immunotherapy
   Salem Billan, Orit Kaidar‐Person, Ziv Gil · 2020 · The Lancet Oncology
7. Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study
   Kobayashi, Tomoko, Iwama, Shintaro, Yasuda, Yoshinori, Okada, Norio, Tsunekawa, Taku, Onoue, Takeshi, Takagi, Hiroshi, Hagiwara, Daisuke, Ito, Yoshihiro, Morishita, Yoshiaki et al. · 2018 · Journal of the Endocrine Society
8. B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade
   Sangwoo S. Kim, Sarek A. Shen, Sayuri Miyauchi, P. Dominick Sanders, Ida Franiak Pietryga, Loren K. Mell, Jorge Silvio Gutkind, Ezra E.W. Cohen, Joseph A. Califano, Andrew B. Sharabi · 2020 · Clinical Cancer Research
9. Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop
   Francesco Marangoni, Ademi Zhakyp, Michela Corsini, Shannon N Geels, Esteban Carrizosa, Martin Thelen, Vinidhra Mani, Jasper N. Pruessmann, Ross D. Warner, Aleksandra J. Ozga et al. · 2021 · Cell
10. Immunotherapy for glioblastoma: the promise of combination strategies
    Mathilde Bausart, Véronique Préat A, Alessio Malfanti · 2022 · Journal of Experimental & Clinical Cancer Research
11. TIGIT: a novel immunotherapy target moving from bench to bedside
    Benjamin Lev Solomon, Ignacio Garrido‐Laguna · 2018 · Cancer Immunology Immunotherapy
12. Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?
    Paul M Hofman, Simon Heeke, Catherine Alix‐Panabières, Klaus Pantel · 2019 · Annals of Oncology
13. Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
    Leilei Ai, Jian Chen, Hao Yan, Qiaojun He, Peihua Luo, Zhifei Xu, Xiaochun Yang · 2020 · Drug Design Development and Therapy
14. STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC
    Lin‐Lin Bu, Guang‐Tao Yu, Lei Wu, L. Mao, Wei‐Wei Deng, Jinmin Liu, Ashok B. Kulkarni, W.F. Zhang, Longjianjie Zhang, Zhi‐Jun Sun · 2017 · Journal of Dental Research
15. Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial
    Yungan Tao, J. Biau, X.S. Sun, C. Sire, Laurent Martin, M. Alfonsi, J.B. Prevost, A. Modesto, C. Lafond, J.M. Tourani et al. · 2022 · Annals of Oncology
16. ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation
    Vendetti, Frank P., Karukonda, Pooja, Clump, David A., Teo, Troy, Lalonde, Ronald, Nugent, Katriana, Ballew, Matthew, Kiesel, Brian F., Beumer, Jan H., Sarkar, Saumendra N. et al. · 2018 · Journal of Clinical Investigation
17. Metabolism in tumor microenvironment: Implications for cancer immunotherapy
    Rongchen Shi, Yi‐Quan Tang, Hongming Miao · 2020 · MedComm
18. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies
    Elísabeth Pérez-Ruiz, Ignacio Melero, Joanna Kopecka, Ana Bela Sarmento‐Ribeiro, Marilina García‐Aranda, Javier De Las Rivas · 2020 · Drug Resistance Updates
19. The Immune Subtypes and Landscape of Squamous Cell Carcinoma
    Bailiang Li, Yi Cui, Dhanya K. Nambiar, John B. Sunwoo, Ruijiang Li · 2019 · Clinical Cancer Research
20. Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis
    Sandhya Manohar, Panagiotis Kompotiatis, Charat Thongprayoon, Wisit Cheungpasitporn, Joerg Herrmann, Sandra M. Herrmann · 2018 · Nephrology Dialysis Transplantation
21. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis
    Daniel Hartman Johnson, Chrystia M. Zobniw, Van Anh Trinh, Junsheng Ma, Roland L. Bassett, Noha Abdel‐Wahab, Jaime E. Anderson, Jennifer E Davis, Jocelyn Joseph, Marc Isamu Uemura et al. · 2018 · Journal for ImmunoTherapy of Cancer
22. Sex- and Gender-Based Pharmacological Response to Drugs
    Franck Mauvais‐Jarvis, Heiner K. Berthold, Ilaria Campesi, Juan Jesús Carrero, Santosh Dhakal, Flavia Franconi, Ioanna Gouni‐Berthold, Mark L. Heiman, Alexandra Kautzky‐Willer, Sabra L. Klein et al. · 2021 · Pharmacological Reviews
23. Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma
    Areti D. Strati, George Koutsodontis, George Papaxoinis, Ilias Angelidis, Martha Zavridou, Panagiota Economopoulou, Ioannis Kotsantis, Margaritis Avgeris, Martine Mazel, Christos Perisanidis et al. · 2017 · Annals of Oncology
24. Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis
    Leitao Sun, Leyin Zhang, Jieru Yu, Yinan Zhang, Xi Pang, Chenghao Ma, Minhe Shen, Shanming Ruan, Harpreet Singh Wasan, Shengliang Qiu · 2020 · Scientific Reports
25. Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC
    Robert Saddawi‐Konefka, Aoife O’Farrell, Farhoud Faraji, Lauren M. Clubb, Michael M. Allevato, Shawn M. Jensen, Bryan S. Yung, Zhiyong Wang, Victoria H. Wu, Nana-Ama A.S. Anang et al. · 2022 · Nature Communications
26. The human papillomavirus (HPV)-related cancer biology: An overview
    Rodrigo Pinheiro Araldi, Thalita Araújo Sant’Ana, Diego Grando Módolo, Thatiana Corrêa de Melo, Diva Denelle Spadacci-Morena, Rita de Cássia Stocco, Janete Maria Cerutti, Edislane Barreiros de Souza · 2018 · Biomedicine & Pharmacotherapy
27. Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
    Jun Gong, Thang Q. Le, Erminia Massarelli, Andrew Eugene Hendifar, Richard Tuli · 2018 · Journal for ImmunoTherapy of Cancer
28. Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer
    Emeka K. Enwere, Elizabeth N. Kornaga, Michelle Liane Dean, Theodora A. Koulis, Tien Phan, Maria Kalantarian, Martin Köbel, Prafull Ghatage, Anthony M. Magliocco, Susan P. Lees‐Miller et al. · 2017 · Modern Pathology
29. Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation
    Robert Louis Ferris, Heinz‐Josef Lenz, Anna Maria Trotta, Jesús García‐Foncillas, Jeltje Schulten, François Audhuy, Marco Carlo Merlano, Gerard Alain Milano · 2017 · Cancer Treatment Reviews
30. Radiotherapy, immunotherapy, and the tumour microenvironment: Turning an immunosuppressive milieu into a therapeutic opportunity
    NE Donlon, Robert F. Power, Conall Hayes, John Vincent Reynolds, Joanne Lysaght · 2021 · Cancer Letters
31. Phase 1/2a, open‐label, multicenter study of RM ‐1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma
    David M. Cognetti, Jennifer Maria Johnson, Joseph Curry, Samith Thomas Kochuparambil, Darren McDonald, Frank E. Mott, Mary J. Fidler, Kerstin M. Stenson, Nilesh Raman Vasan, Mohammad Razaq et al. · 2021 · Head & Neck
32. Immune checkpoint inhibitors and elderly people: A review
    Amaury Daste, Charlotte Domblides, Marine Gross‐Goupil, Camille Chakiba, Amandine Quivy, Valérie Cochin, Erwan de Monès, Nicolas Larmonier, Pierre Soubeyran, Alain Ravaud · 2017 · European Journal of Cancer
33. Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma
    Linda L Tran, C. Allen, Roy Xiao, E. Moore, Ruth J. Davis, So-Jin Park, Katie K. Spielbauer, C. Van Waes, N. Schmitt · 2017 · Cancer immunology research
34. PD-1 blockade inhibits osteoclast formation and murine bone cancer pain
    Kaiyuan Wang, Yun Gu, Yihan Liao, Sangsu Bang, Christopher R. Donnelly, Chen Ouyang, Xueshu Tao, Anthony J. Mirando, Matthew J. Hilton, Ru‐Rong Ji · 2020 · Journal of Clinical Investigation
35. Precision medicine in head and neck cancer.
    O. Kaidar-Person, Z. Gil, S. Billan · 2018 · Drug resistance updates
36. Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)
    on behalf of the European Conference on Infections in Leukemia (ECIL), Georg Maschmeyer, Julien De Greef, Sibylle C. Mellinghoff, Annamaria Nosari, Anne Thiébaut, Anne Bergeron, Tomás Franquet, Nicole M. A. Blijlevens, Johan A. Maertens · 2019 · Leukemia
37. Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma
    Mohamed E. Salem, Alberto Puccini, Joanne Xiu, Derek Raghavan, Heinz‐Josef Lenz, Wolfgang Michael Korn, Anthony Frank Shields, Philip A. Philip, John Lindsay Marshall, Richard M. Goldberg · 2018 · The Oncologist
38. Snail-overexpressing Cancer Cells Promote M2-Like Polarization of Tumor-Associated Macrophages by Delivering MiR-21-Abundant Exosomes
    Chia-Hsin Hsieh, Shyh‐Kuan Tai, Muh‐Hwa Yang · 2018 · Neoplasia
39. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Khalil Saleh, Amaury Daste, Nicolas Martin, Elvire Pons Tostivint, Anne Auperin, Ruth Gabriela Herrera Gómez, N. Baste-Rotllan, François Bidault, Joël Guigay, Christophe Le Tourneau et al. · 2019 · European Journal of Cancer
40. Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer
    Nicola Gaynor, John Paul Crown, Denis Martin Collins · 2020 · Seminars in Cancer Biology
41. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta‐analysis
    Néstor Rubio‐Infante, Yoel A. Ramírez‐Flores, Elena C. Castillo, Omar Lozano, Gerardo García‐Rivas, Guillermo Torre‐Amione · 2021 · European Journal of Heart Failure
42. Diagnostic Tumor Markers in Head and Neck Squamous Cell Carcinoma (HNSCC) in the Clinical Setting
    Panagiota Economopoulou, Remco de Bree, Ioannis Kotsantis, Amanda K. Psyrri · 2019 · Frontiers in Oncology
43. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
    Jean‐Marie Michot, Julien Lazarovici, Ashley Tieu, Stéphane Champiat, Anne-Laure Voisin, Mikaël Ebbo, Bertrand Godeau, Marc Michel, Vincent Ribrag, Olivier Lambotte · 2019 · European Journal of Cancer
44. A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer
    Cristina P. Rodriguez, Qian Vicky Wu, Jenna M. Voutsinas, Jonathan R. Fromm, Xiuyun Jiang, Venu Gopal Pillarisetty, Sylvia M. Lee, Rafael Santana-Dávila, Bernardo Goulart, Christina S. Baik et al. · 2019 · Clinical Cancer Research
45. Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades
    Hao Chen, Wei Chong, Qian Wu, Yueliang Yao, Min Mao, Xin Wang · 2019 · Frontiers in Immunology
46. Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy
    Shixiang Wang, Li An Cowley, Xuesong Liu · 2019 · Molecules
47. Tumor immune microenvironment in head and neck cancers
    Samantha M. Y. Chen, Alexandra L. Krinsky, Rachel A. Woolaver, Xiaoguang Wang, Zhangguo Chen, Jing Hong Wang · 2020 · Molecular Carcinogenesis
48. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing
    Danny Rischin, Michael Robert Migden, Annette May Ling Lim, Chrysalyne Delling Schmults, Nikhil I. Khushalani, Brett G.M. Hughes, Dirk Schadendorf, Lara Ann Dunn, Leonel Fernando Hernandez-Aya, Anne Lynn S. Chang et al. · 2020 · Journal for ImmunoTherapy of Cancer
49. Galectin-1–driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance
    Dhanya K. Nambiar, Todd Anthony Aguilera, Hongbin Cao, Shirley Kwok, Christina S. Kong, Joshua Daniel Bloomstein, Zemin Wang, Vangipuram S. Rangan, Dadi Jiang, Rie von Eyben et al. · 2019 · Journal of Clinical Investigation
50. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study
    Yamauchi, Ichiro, Sakane, Yoriko, Fukuda, Yorihide, Fujii, Toshihito, Taura, Daisuke, Hirata, Masakazu, Hirota, Keisho, Ueda, Yohei, Kanai, Yugo, Yamashita, Yui et al. · 2017 · Thyroid
51. Tobacco Smoking-Associated Alterations in the Immune Microenvironment of Squamous Cell Carcinomas
    Alexis Desrichard, Fengshen Kuo, Diego Chowell, Ken-Wing Lee, Nadeem Riaz, Richard J. Wong, Timothy An-thy Chan, Luc G.T. Morris · 2018 · JNCI Journal of the National Cancer Institute
52. Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases
    Umbreen Hafeez, Hui Kong Gan, Andrew Mark Scott · 2018 · Current Opinion in Pharmacology
53. Inhibitors of the PD-1 Pathway in Tumor Therapy
    Martin W. LaFleur, Yuki Muroyama, Charles G. Drake, Arlene H. Sharpe · 2018 · The Journal of Immunology
54. Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651
    Robert I. Haddad, Kevin Joseph Harrington, Makoto Tahara, Robert Louis Ferris, Maura L. Gillison, Jérôme Fayette, Amaury Daste, P. Koralewski, Bogdan A. Żurawski, Miren Taberna et al. · 2022 · Journal of Clinical Oncology
55. Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4
    Zhiyong Wang, Victoria H. Wu, Michael M. Allevato, Mara Gilardi, Yudou He, Juan Luis Callejas‐Valera, Lynn A. Vitale-Cross, Daniel Martı́n, Panomwat Amornphimoltham, James Mcdermott et al. · 2019 · Nature Communications
56. Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
    Hiro Sato, Noriyuki Okonogi, Takashi Nakano · 2020 · International Journal of Clinical Oncology
57. Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy
    Maxim Alekseevich Shevtsov, Hiro Sato, Gabriele Multhoff, Atsushi Shibata · 2019 · Frontiers in Oncology
58. Current Immunotherapies for Glioblastoma Multiforme
    Boyuan Huang, Xuesong Li, Yuntao Li, Jin Zhang, Zhitao Zong, Hongbo Zhang · 2021 · Frontiers in Immunology
59. Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model
    Benjamin E. Jin, Tracy E. Campbell, Lindsey M. Draper, Sanja Stevanović, Bianca Weißbrich, Zhiya Yu, Nicholas P. Restifo, Steven A. Rosenberg, Cornelia Liu Trimble, Christian S. Hinrichs · 2018 · JCI Insight
60. Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials
    Diana Magee, Amanda Elizabeth Hird, Zachary William Abraham Klaassen, Srikala S. Sridhar, R. K. Nam, Christopher J. D. Wallis, Girish S. Kulkarni · 2020 · Annals of Oncology
61. The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study
    Matteo Santoni, Alessandro Rizzo, Veronica Mollica, Marc Ryan Matrana, Matteo Rosellini, Luca Faloppi, Andrea Marchetti, Nicola Battelli, Francesco Massari · 2022 · Critical Reviews in Oncology/Hematology
62. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma
    Jian Wang, Hao Sun, Qin Zeng, Xue‐Jun Guo, Hui Wang, Huan‐Huan Liu, Zhong‐Yi Dong · 2019 · Scientific Reports
63. Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity
    Valsamo Anagnostou, Mark M. Yarchoan, Aaron Richard Hansen, Hao Wang, Franco Verde, Elad Sharon, Deborah E. Collyar, Laura Q.M. Chow, Patrick M. Forde · 2017 · Clinical Cancer Research
64. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers
    Muhammad Umair Mushtaq, Athanasios Papadas, Adam C. Pagenkopf, Evan Flietner, Zachary T. Morrow, Sibgha Gull Chaudhary, Fotis A. Asimakopoulos · 2018 · Journal for ImmunoTherapy of Cancer
65. Advances in immune checkpoint inhibitors for bone sarcoma therapy
    Pichaya Thanindratarn, Dylan C. Dean, Scott D. Nelson, Francis John Hornicek, Zhenfeng Duan · 2019 · Journal of bone oncology
66. Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma
    Jacob H. Rasmussen, Giedrius Lelkaitis, Katrin Håkansson, Ivan R. Vogelius, Helle Hjorth Johannesen, Barbara Malene Fischer, Søren Møller Bentzen, Lena Specht, Claus Andrup Kristensen, Christian von Buchwald et al. · 2019 · British Journal of Cancer
67. TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials
    Khalil Choucair, Susan M. Morand, Laura Stanbery, Gerald M. Edelman, Lance D. Dworkin, John J. Nemunaitis · 2020 · Cancer Gene Therapy
68. Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?
    Mohammad Hossein Kazemi, Maryam Sadri, Alireza Najafi, Ali R. Rahimi, Zeinab Baghernejadan, Hossein Khorramdelazad, Reza Falak · 2022 · Frontiers in Immunology
69. Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer
    Sibi Raj, Kavindra Kumar Kesari, Arun J. Kumar, Brijesh Rathi, Ashok Kumar Sharma, Piyush Kumar Gupta, Saurabh Kumar Jha, Niraj Kumar Jha, Petr Sláma, Shubhadeep Roychoudhury et al. · 2022 · Molecular Cancer
70. PD-L1 Mediates Dysfunction in Activated PD-1+ NK Cells in Head and Neck Cancer Patients
    Fernando Concha‐Benavente, Benjamin Kansy, Jessica M. Moskovitz, Jennifer D. Moy, Uma R. Chandran, Robert Louis Ferris · 2018 · Cancer Immunology Research
71. Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer
    Akinori Sasaki, Yoshiaki Nakamura, Saori Mishima, Akihito Kawazoe, Yasutoshi Kuboki, Hideaki Bando, Takashi Kojima, Toshihiko Doi, Atsushi Ohtsu, Takayuki Yoshino et al. · 2019 · Gastric Cancer
72. Host Immunity Following Near-Infrared Photoimmunotherapy Is Enhanced with PD-1 Checkpoint Blockade to Eradicate Established Antigenic Tumors
    Tadanobu Nagaya, Jay Friedman, Yasuhiro Maruoka, Fusa Ogata, Shuhei Okuyama, Paúl E. Clavijo, Peter L. Choyke, Clint Tanner Allen, Hisataka Kobayashi · 2019 · Cancer Immunology Research
73. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab
    Kimbara, Shiro, Fujiwara, Yutaka, Iwama, Shintaro, Ohashi, Ken, Kuchiba, Aya, Arima, Hiroshi, Yamazaki, Naoya, Kitano, Shigehisa, Yamamoto, Noboru, Ohe, Yuichiro · 2018 · Cancer Science
74. Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials
    Sirisha L. Mushti, Flora A. Mulkey, Rajeshwari Sridhara · 2018 · Clinical Cancer Research
75. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis
    Qiang Su, Emily C. Zhu, Jingbo Wu, Teng Li, Yanli Hou, Diya Wang, Zu‐Hua Gao · 2019 · Frontiers in Immunology
76. Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use
    Robert Louis Ferris, Lisa Francesca Licitra, Jérôme Fayette, Caroline Even, George R. Blumenschein, Kevin Joseph Harrington, Joël Guigay, Everett E. Vokes, Nabil F. Saba, Robert I. Haddad et al. · 2019 · Clinical Cancer Research
77. Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
    Athanassios E. Argiris, Kevin Joseph Harrington, Makoto Tahara, Jeltje Schulten, Pauline Chomette, Ana Ferreira Castro, Lisa Francesca Licitra · 2017 · Frontiers in Oncology
78. Immunotherapy for Head and Neck Squamous Cell Carcinoma
    Jessica M. Moskovitz, Jennifer D. Moy, Robert Louis Ferris · 2018 · Current Oncology Reports
79. Tumor-associated B cells and humoral immune response in head and neck squamous cell carcinoma
    Axel Lechner, Hans Schlößer, Martin Thelen, Kerstin Wennhold, Sacha I. Rothschild, Ramona Gilles, Alexander Quaas, Oliver G. Siefer, Christian Ulrich Huebbers, Engin Cukuroglu et al. · 2019 · OncoImmunology
80. The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy
    Linda Quatrini, Francesca Romana Mariotti, Enrico Munari, Nicola Tumino, Paola Vacca, Lorenzo Moretta · 2020 · Cancers
81. Head and neck cancer: Current challenges and future perspectives
    Gh Rasool Bhat, Rosalie G. Hyole, Jiong Li · 2021 · Advances in cancer research
82. Neoadjuvant Chemoimmunotherapy for the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Clinical Trial
    Zhanjie Zhang, Bian Wu, Gang Peng, Guixiang Xiao, Jing Huang, Qian Ding, Chengzhang Yang, Xingao Xiong, Hui Ma, Liangliang Shi et al. · 2022 · Clinical Cancer Research
83. BMI1 Inhibition Eliminates Residual Cancer Stem Cells after PD1 Blockade and Activates Antitumor Immunity to Prevent Metastasis and Relapse
    Lingfei Jia, Wuchang Zhang, Cun‐Yu Wang · 2020 · Cell stem cell
84. Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis
    Giuseppe Viscardi, Antonino Carmelo Tralongo, Francesco Massari, Matteo Lambertini, Veronica Mollica, Alessandro Rizzo, Francesca Comito, Raimondo Di Liello, Salvatore Alfieri, Martina Imbimbo et al. · 2022 · European Journal of Cancer
85. Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities
    Clélia Coutzac, Julien Adam, Émilie Soularue, Michael Collins, Antoine Racine, Charlotte Mussini, Lisa Boselli, Nyam Kamsu-Kom, Christine Mateus, Mélinda Charrier et al. · 2017 · Journal of Crohn s and Colitis
86. Tumor microenvironment: an evil nexus promoting aggressive head and neck squamous cell carcinoma and avenue for targeted therapy
    Ajaz Ahmad Bhat, Parvaiz Yousuf, Nissar Ahmad Wani, Arshi Rizwan, Shyam Singh Chauhan, Mushtaq Ahmad Siddiqi, Davide Bedognetti, Wael M. El-Rifai, Michael Paul Frenneaux, Surinder K. Batra et al. · 2021 · Signal Transduction and Targeted Therapy
87. Targeting immune checkpoints in breast cancer: an update of early results
    Cinzia Solinas, Andrea Gombos, Sofiya Latifyan, Martine J Piccart, Marleen Kok, Laurence Buisseret · 2017 · ESMO Open
88. Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis
    Monica Khunger, Adrián Vladimir Hernández, Vinay Pasupuleti, Sagar Rakshit, Nathan A. Pennell, James P. Stevenson, Sanjay Mukhopadhyay, Kurt Alex Schalper, Vamsidhar Velcheti · 2017 · JCO Precision Oncology
89. Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies
    Michael Collins, Jean‐Marie Michot, F.X. Danlos, Charlotte Mussini, Émilie Soularue, Christine Mateus, Delphine Loirat, Anthony Buisson, Isabelle Rosa, Olivier Lambotte et al. · 2017 · Annals of Oncology
90. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies
    Julius Strauss, Margaret Elena Gatti-Mays, Byoung Chul Cho, Andrew Hill, Sébastien Salas, Edward Francis McClay, Jason Mark Redman, Houssein Abdul Sater, Renee Nicole Donahue, Caroline Jochéms et al. · 2020 · Journal for ImmunoTherapy of Cancer
91. Pasotuxizumab, a Bite ® Immune Therapy for Castration-Resistant Prostate Cancer: Phase I, Dose-Escalation Study Findings
    Hummel, Horst-Dieter, Kufer, Peter, Grüllich, Carsten, Seggewiss-Bernhardt, Ruth, Deschler-Baier, Barbara, Chatterjee, Manik, Goebeler, Maria-Elisabeth, Miller, Kurt, de Santis, Maria, Loidl, Wolfgang et al. · 2021 · Immunotherapy
92. PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors
    Harriet M. Kluger, Christopher R. Zito, Gabriela Turcu, Marina K. Baine, Hongyi Zhang, Adebowale Adeniran, Mario Sznol, David L. Rimm, Yuval Kluger, Lieping Chen et al. · 2017 · Clinical Cancer Research
93. Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine
    Yee Sun Tan, Kanokwan Sansanaphongpricha, Yuying Xie, Christopher R. Donnelly, Xiaobo Luo, Blake R. Heath, Xinyi Zhao, Emily Light Bellile, Hongxiang Hu, Hongwei Chen et al. · 2018 · Clinical Cancer Research
94. Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study
    Alessandro Rizzo, Matteo Santoni, Veronica Mollica, Francesco Ottavio Logullo, Matteo Rosellini, Andrea Marchetti, Luca Faloppi, Nicola Battelli, Francesco Massari · 2021 · Expert Opinion on Drug Metabolism & Toxicology
95. Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker–based immunotherapy
    Feihu Wang, Dongqing Xu, Hao Su, Weijie Zhang, Xuanrong Sun, Maya K. Monroe, Rami W. Chakroun, Zongyuan Wang, Wenbing Dai, Richard Oh et al. · 2020 · Science Advances
96. Endocrine side effects of cancer immunotherapy
    Cukier, Priscilla, Santini, Fernando C, Scaranti, Mariana, Hoff, Ana O · 2017 · Endocrine-Related Cancer
97. International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ‐HN43: Phase IV
    Susanne Singer, Cecilie Delphin Amdal, Eva B. Hammerlid, Iwona M. Tomaszewska, Joaquim Castro Silva, Hisham Mohamed Mehanna, M.A. Santos, Johanna Inhestern, Christine Brannan, Noam Yarom et al. · 2019 · Head & Neck
98. Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics
    Sayuri Miyauchi, Sangwoo S. Kim, John Pang, Kathryn Ann Gold, Jorge Silvio Gutkind, Joseph A. Califano, Loren K. Mell, Ezra E.W. Cohen, Andrew B. Sharabi · 2019 · Clinical Cancer Research
99. Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells
    Rebekka Duhen, Carmen Ballesteros‐Merino, Alexandra K. Frye, Eric Tran, Venkatesh Rajamanickam, Shu‐Ching Chang, Yoshinobu Koguchi, Carlo Bruno Bifulco, Brady M. Bernard, Rom S. Leidner et al. · 2021 · Nature Communications
100. Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC)
     Emma J. de Ruiter, Frans J. Mulder, Bregje M Koomen, Ernst‐Jan M. Speel, Mari F.C.M. van den Hout, Reinout H. de Roest, Elisabeth Bloemena, Lot A. Devriese, Stefan M. Willems · 2020 · Modern Pathology